Valneva Reports Mixed Financial Results Amid Strategic Pivots

The French vaccine developer Valneva has released preliminary figures for 2025 and issued initial guidance for the current fiscal year. The financial snapshot presents a complex picture, marked by a divergence between total revenue growth and a decline in core product sales, alongside a significant reduction in the company’s cash reserves.

A notable development in Valneva’s year-end position is the state of its liquidity. The company’s cash and cash equivalents fell substantially to €109.7 million as of December 31, 2025, down from €168.3 million at the end of 2024. Management attributes this decrease to continued investment in its research and development pipeline.

On the revenue front, the preliminary total for 2025 reached Read more...